Core One Labs Inc.

12/02/2023

Core One Labs’ Akome Reveals Impressive Results for its Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods

Read Press Release: https://core1labs.com/company-news/core-one-labs-akome-reveals-impressive-results-for-its-psychedelic-bio-compounds-designed-to-target-alzheimers-and-parkinsons-showing-potential-to-outperform-current-treatm

08/04/2023

Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease

Read Press Release:

Vancouver, British Columbia, Canada – August 4, 2023 – Core One Labs Inc. (CSE: COOL) (OTCQB: CLABF) (Frankfurt: LD6, WKN: A3CSSU), (the “Company” or “Core One”) is delighted to announce the receipt of additional positive results from its second round (“Round 2”) of Stage 1 animal mo...

08/02/2023

Core One Labs’, Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying from Mushroom Biomass

Read Press Release:

Vancouver, British Columbia, Canada – August 1, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) proudly announces a significant milestone in its pursuit of cutting-edge psychedelic research and development. Awakened Biosc...

07/28/2023

Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Read Press Release:

Vancouver, British Columbia, Canada – July 28, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), is excited to share positive results from its first round of Stage 1 animal model studies (“Round 1”), conducted by its r...

07/21/2023

Core One Labs Enters into Letter of Intent for First Sale of its Compounds

Read Press Release:

Vancouver, British Columbia, Canada – July 21, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly-owned subsidiary, GMP Drug Inc. (“GMP Drug”), has entered into a non-binding letter...

07/11/2023

Core One’s Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic

Vancouver, British Columbia, Canada – July 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has incorporated a state-of-the-art, high density...

07/11/2023

Core One’s Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Production Method

Vancouver, British Columbia, Canada – July 7, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. (“Vocan”), has completed final steps of...

05/05/2023

Core One in Talks with Multiple Companies to Supply

Read Press Release:

Vancouver, British Columbia, Canada – May 5, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it is in discussions with several pharmaceutical laboratories and research organizations to supply the...

05/02/2023

Core One Labs’ GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Prodrugs with Long-established Compounding Pharmacy

Read Press Release:

Vancouver, British Columbia, Canada – May 1, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly-owned subsidiaries, GMP Drug Inc., and Awakened Biosciences Inc. (“Awakened”) will comm...